

# Development of a Neuroendocrine Prostate Cancer Therapy by Targeting NF- $\kappa$ B Signaling via Neddylaton inhibition

Korea Research Institute of Chemical Technology



ONCOLOGY	Lead
Product Type	Small molecules
Indication	Neuroendocrine Prostate Cancer (NEPC)
Target	NEDDylation pathway
MoA(Mechanism of Action)	NF- $\kappa$ B signaling pathway inhibition through regulation of NEDDylation (E1-E2 enzymes)
Competitiveness	<ul style="list-style-type: none"> <li>Platinum-based chemotherapy is currently the only available treatment for NEPC.</li> <li>Potential competing agents include MLN4924 (Pevonedistat), Taxanes (docetaxel), and cabazitaxel (JEVTANA®).</li> </ul>
Development Stage	Lead
Route of Administration	oral administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*